Vericel (VCEL) Other Non-Current Assets (2019 - 2026)
Vericel (VCEL) posted Other Non-Current Assets of $233000.0 for Q2 2026, down 19.1% sequentially from $288000.0 in Q1 2026, and down 47.87% YoY from $447000.0 in Q2 2025.
Analysis
Vericel (VCEL) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Vericel has reported Other Non-Current Assets for 8 years, with the latest figure at $233000.0 in Q2 2026.
- Quarterly Other Non-Current Assets fell 47.87% year-over-year to $233000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $233000.0 (down 47.87% YoY) and the FY2025 annual result came in at $341000.0, down 38.67% from the prior year.
- Other Non-Current Assets fell to $233000.0 in Q2 2026 per VCEL's latest filing, from $288000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $43.0 million in Q2 2023 and troughed at $233000.0 in Q2 2026.
- A 5-year average of $3.7 million and a median of $690500.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets soared 2830.81% in 2022, then tumbled 98.46% in 2024.
- Over 5 years, Other Non-Current Assets stood at $1.3 million in 2022, then plunged by 40.83% to $771000.0 in 2023, then dropped by 27.89% to $556000.0 in 2024, then slumped by 38.67% to $341000.0 in 2025, then sank by 31.67% to $233000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $233000.0, $288000.0, and $341000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 233,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 233,000.00 |
| Mar 31, 2026 | 288,000.00 |
| Dec 31, 2025 | 341,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 501,000.00 |
| Dec 31, 2024 | 556,000.00 |
| Sep 30, 2024 | 610,000.00 |
| Jun 30, 2024 | 664,000.00 |
| Mar 31, 2024 | 717,000.00 |
| Dec 31, 2023 | 771,000.00 |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 43.00 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 6.18 Mn |
| Mar 31, 2022 | 6.18 Mn |
| Dec 31, 2021 | 317,000.00 |
| Sep 30, 2021 | 219,000.00 |